DMAC

DiaMedica Therapeutics Inc.

BS score 26.0LOWPHASE3 · mkt cap $333.0M · rev ttm $0

drug hypothesis

DM199 (recombinant human tissue kallikrein) modulates Kallikrein-kinin system (B2 bradykinin receptor pathway); specific molecular target not explicitly stated in provided data to treat Acute Ischemic Stroke.

moa:DM199 is a recombinant human tissue kallikrein enzyme that cleaves kininogen to produce bradykinin, leading to vasodilation, improved cerebral blood flow, and potential neuroprotective effects in acute ischemic stroke

score breakdown

trial design20

base rate disconnect5

language red flags80

composite26.0

valuation analysis

market cap$333.0M

revenue ttm$0

phasePHASE3

historical base rate38%

disconnect ratio0.2x

lead trialNCT02868996

meta

cik0001401040

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 2 randomized, double-blind, placebo-controlled trial enrolling 92 subjects with acute ischemic stroke; primary completion date January 23, 2020

primary endpoint:Number of participants with treatment-related adverse events as assessed by CTCAE v4.3 at 90 days (safety/tolerability endpoint)

claimed differentiation

Not provided in available data

language red flags

Insufficient SEC filing text provided to assess company language (only section number '3' visible)
Target and mechanism not clearly defined in available data
No differentiation claims visible in provided information
Cannot assess for hedging or promotional language without full filing text

company-stated risks

Not explicitly stated in provided data